Patents by Inventor Hans-Michael Eggenweiler

Hans-Michael Eggenweiler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050176714
    Abstract: Pyridazine derivatives of the formula (I) act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
    Type: Application
    Filed: May 12, 2003
    Publication date: August 11, 2005
    Applicant: Merck Patent GmbH
    Inventors: Hans-Michael Eggenweiler, Michael Wolf
  • Patent number: 6884800
    Abstract: Imidazole compounds of the formula I in which R1 and R2, independently of one another, each denote A1, OA1, SA1 or Hal, A1 denotes H, A, alkenyl, cycloalkyl or alkylenecycloalkyl, A denotes alkyl having 1-10 carbon atoms, Hal denotes F, Cl, Br or I, and X denotes O, S, SO or SO2, and their physiologically acceptable salts and/or solvates, as phosphodiesterase VII inhibitors, and their use for the preparation of a medicament.
    Type: Grant
    Filed: October 31, 2000
    Date of Patent: April 26, 2005
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Hans-Michael Eggenweiler, Rochus Jonas, Michael Wolf, Michael Gassen, Thomas Welge
  • Publication number: 20050070529
    Abstract: The invention relates to the use of type 4 phosphodiesterase inhibitors to treat myocardial diseases.
    Type: Application
    Filed: January 15, 2002
    Publication date: March 31, 2005
    Applicant: Merk Pantent GmbH
    Inventors: Arne Sutter, Thomas Ehring, Thomas Welge, Klause Minck, Claudia Wilm, Michael Gassen, Hans-Michael Eggenweiler, Michael Wolf, Pierre Schelling, Norbert Beier, Joachim Leibrock
  • Publication number: 20050059686
    Abstract: Pyrrolopyrimidine derivatives of the formula I in which R3, R4, R5, R6 and X are as defined in claim 1, act as phosphodiesterase VII inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
    Type: Application
    Filed: November 8, 2002
    Publication date: March 17, 2005
    Inventors: Hans-Michael Eggenweiler, Michael Wolf
  • Publication number: 20040261190
    Abstract: Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3′ and R4 have the meanings given in claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
    Type: Application
    Filed: May 4, 2004
    Publication date: December 30, 2004
    Inventors: Hans-Michael Eggenweiler, Michael Wolf, Norbert Beier, Pierre Schelling, Thomas Ehring
  • Publication number: 20040259863
    Abstract: The invention relates to the use of type 4 phosphodiesterase inhibitors (PDE IV inhibitors) to treat diseases and to combinations of PDE IV inhibitors with other drugs.
    Type: Application
    Filed: April 30, 2004
    Publication date: December 23, 2004
    Inventors: Hans-Michael Eggenweiler, Michael Wolf
  • Publication number: 20040242595
    Abstract: Pyrimidine derivatives of formula (I) and 1
    Type: Application
    Filed: April 2, 2004
    Publication date: December 2, 2004
    Inventors: Hans-Michael Eggenweiler, Manfred Baumgarth, Pierre Schelling, Norbert Beier, Maria Christadler
  • Publication number: 20040235845
    Abstract: Use of phosphodiesterase IV inhibitors and/or physiologically acceptable salts thereof for the preparation of a medicament for the treatment of osteoporosis, tumours, tumour metastases, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, ulcerative collitis and AIDS.
    Type: Application
    Filed: April 12, 2004
    Publication date: November 25, 2004
    Inventors: Hans-Michael Eggenweiler, Michael Wolf
  • Publication number: 20040176252
    Abstract: Triazine derivatives of the formula (I) and physiologically acceptable salts and solvates thereof, in which R1, R2, A and R5 are as defined in claim 1, exhibit phosphodiesterase IV inhibition and can be employed for the treatment of allergic diseases, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory diseases, autoimmune diseases, such as, for example, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumour growth or tumour metastases, sepsis, memory disorders, atherosclerosis and AIDS, furthermore for inhibiting the formation of TNF&agr;.
    Type: Application
    Filed: January 20, 2004
    Publication date: September 9, 2004
    Inventors: Hans-Michael Eggenweiler, Michael Wolf, Norbert Beier, Joachim Leibrock, Pierre Schelling, Michael Gassen, Thomas Ehring
  • Patent number: 6780867
    Abstract: Thienopyrimidines of the formula (I) and their physiologically acceptable salts, in which R1, R2 and X are as defined in claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of illnesses of the cardiovascular system and for the treatment and/or therapy of impotence.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: August 24, 2004
    Assignee: Merck Patent GmbH
    Inventors: Rochus Jonas, Hans-Michael Eggenweiler, Pierre Schelling, Maria Christadler, Norbert Beier
  • Patent number: 6777419
    Abstract: Pyrazolo[4,3-d]pyrimidines of the formula I and their physiologically acceptable salts, in which R1, R2, R3, R4 and X have the meanings indicated in Claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of disorders of the cardiovascular system and for the treatment and/or therapy of potency disorders.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: August 17, 2004
    Assignee: Merck Patent GmbH
    Inventors: Rochus Jonas, Hans-Michael Eggenweiler, Pierre Schelling, Maria Christadler, Norbert Beier
  • Publication number: 20040138279
    Abstract: Imidazole derivatives of the formula I 1
    Type: Application
    Filed: January 5, 2004
    Publication date: July 15, 2004
    Inventors: Hans-Michael Eggenweiler, Rochus Jonas, Michael Wolf, Michael Gassen, Oliver Poschke
  • Patent number: 6737436
    Abstract: Compounds of the formula I in which R1 and R2, independently of one another, each denote H, A, OA, SA or HaI, R3 denotes H or A, R4 denotes A or NH2, R5 denotes H, NH2, NHA or NA2, A denotes alkyl having 1 to 10 carbon atoms, alkenyl, cycloalkyl or alkylenecycloalkyl, Hal denotes F, Cl, Br or I, and their physiologically acceptable salts and/or solvates, as phosphodiesterase VII inhibitors.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: May 18, 2004
    Assignee: Merck Patent GmbH
    Inventors: Hans-Michael Eggenweiler, Rochus Jonas, Michael Wolf, Michael Gassen, Thomas Welge
  • Publication number: 20040077664
    Abstract: Pharmaceutical preparation comprising at least one phosphodiesterase V inhibitor and at least one nitrate for the preparation of a medicament for the treatment of angina, high blood pressure, pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, dextrocardiac insufficiency, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, strokes, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, renal insufficiency and liver cirrhosis.
    Type: Application
    Filed: July 30, 2003
    Publication date: April 22, 2004
    Inventors: Hans-Michael Eggenweiler, Volker Eiermann, Pierre Schelling
  • Publication number: 20040072846
    Abstract: The invention relates to a pharmaceutical preparation containing at least one compound of formula (I) wherein R1, R2, R3, R4, n and X have the same meaning as cited in claim 1, and the physiologically acceptable salts thereof and/or solvates and a) at least one antithrombotic or b) at least one calcium antagonist or c) at least one prostaglandin or prostaglandin derivative for producing a medicament for treating angina, high blood pressure, pulmonary hypertension, congestive heart failure (CHF), chromic obstructive pulmonary disease (COPD), pulmonary heart disease, right ventricular failure, astheriosclerosis, conditions of reduced cardiovascular patency, peripheral vascular illnesses, cerebral apoplexy, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, kidney failure, cirrhosis of the liver and for treating female sexual problems.
    Type: Application
    Filed: June 19, 2003
    Publication date: April 15, 2004
    Inventors: Hans-Michael Eggenweiler, Volker Eiermann
  • Publication number: 20040067954
    Abstract: This invention relates to compounds of the formula (I) in which R1, R2, R3, X and Q are as defined above and their use as PDE IV inhibitors.
    Type: Application
    Filed: June 23, 2003
    Publication date: April 8, 2004
    Inventors: Hans-Michael Eggenweiler, Michael Wolf, Norbert Beier, Joachim Leibrock, Michael Gassen, Thomas Ehring
  • Publication number: 20040063730
    Abstract: The invention relates to a pharmaceutical preparation containing at least one compound of formula (I), wherein R1, R2, R3, R4 and X have the meanings as cited in claim No. 1, and to their physiologically safe salts and/or solvates, and containing; a) at least one antithrombotic agent or; b) at least one calcium antagonist or; c) at least on prostaglandin or prostaglandin derivative for producing a medicament used for treating angina, hypertension, pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, right ventricular failure, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, cerebrovascular accident, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumors, kidney failure, cirrhosis of the liver, and for treating female sexual dysfunctions.
    Type: Application
    Filed: June 19, 2003
    Publication date: April 1, 2004
    Inventors: Hans-Michael Eggenweiler, Volker Eiermann
  • Publication number: 20040063731
    Abstract: Pharmaceutical preparation comprising at least one phosphodiesterase V inhibitor have, and/or physiologically acceptable salts and/or solvates thereof and at least one endothelin receptor antagonist for the preparation of a medicament for the treatment of angina, high blood pressure, high pulmonary pressure, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, dextrocardiac insufficiency, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, strokes, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, renal insufficiency, liver cirrhosis, erectile dysfunction and for the treatment of female sexual disorders.
    Type: Application
    Filed: July 31, 2003
    Publication date: April 1, 2004
    Inventors: Hans-Michael Eggenweiler, Volker Eiermann, Pierre Schelling
  • Publication number: 20040063943
    Abstract: The invention relates to compounds of the formula (I) in which R1, E2 and X are as defined above.
    Type: Application
    Filed: June 20, 2003
    Publication date: April 1, 2004
    Inventors: Hans-Michael Eggenweiler, Harry Schwartz, Pierre Schelling, Norbert Beier, Maria Christadler
  • Publication number: 20040058940
    Abstract: The invention relates to a pharmaceutical formulation containing at least one compound of formula (1) wherein R1, R2, and X have the same meaning as cited in claim 1, and the physiologically acceptable salts thereof and/or solvates and a) at least one antithrombotic or b) at least one calcium antagonist or c) at least one prostaglandin or prostaglandin derivative for producing a medicament for treating angina, high blood pressure, pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), pulmonary heart disease, right ventricular failure, atheriosclerosis, permeability conditions of reduced cardiovascular patency, peripheral vascular illnesses, cerebral apoplexy, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, kidney failure, cirrhosis of the liver and for treating female sexual problems.
    Type: Application
    Filed: June 19, 2003
    Publication date: March 25, 2004
    Inventors: Hans-Michael Eggenweiler, Volker Eiermann